Literature DB >> 8805707

Unique fold and active site in cytomegalovirus protease.

X Qiu1, J S Culp, A G DiLella, B Hellmig, S S Hoog, C A Janson, W W Smith, S S Abdel-Meguid.   

Abstract

Human herpesviruses are responsible for a variety of diseases. They are divided into three subfamilies: alpha includes herpes simplex viruses (HSV-1 and HSV-2) and varicella-zoster virus (VZV); beta includes cytomegalovirus (CMV) and human herpesvirus-6 (HHV-6); and gamma includes Epstein-Barr virus (EBV). Each virus encodes a serine protease that is essential for its replication and is a potential target for therapeutic intervention. Human CMV is a ubiquitous opportunistic pathogen that can result in life-threatening infections in congenitally infected infants, immunocompromised individuals and immunosuppressed cancer or transplant patients. Here we report the crystal structure of human CMV protease at 2.5 angstroms resolution. The structure reveals a fold that has not been reported for any other serine protease, and an active site consisting of a novel catalytic triad in which the third member is a histidine instead of an aspartic acid, or possibly a catalytic tetrad consisting of a serine, two histidines and an aspartic acid. An unusual dimer interface that is important to the protease activity has also been identified.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8805707     DOI: 10.1038/383275a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  34 in total

1.  Cytomegalovirus capsid protease: biological substrates are cleaved more efficiently by full-length enzyme (pUL80a) than by the catalytic domain (assemblin).

Authors:  Steve M Fernandes; Edward J Brignole; Kanchan Taori; Wade Gibson
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

2.  Displacements of prohead protease genes in the late operons of double-stranded-DNA bacteriophages.

Authors:  Jing Liu; Arcady Mushegian
Journal:  J Bacteriol       Date:  2004-07       Impact factor: 3.490

Review 3.  Procapsid assembly, maturation, nuclear exit: dynamic steps in the production of infectious herpesvirions.

Authors:  Giovanni Cardone; J Bernard Heymann; Naiqian Cheng; Benes L Trus; Alasdair C Steven
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

4.  Alterations in catalytic activity and virus maturation produced by mutation of the conserved histidine residues of herpes simplex virus type 1 protease.

Authors:  R B Register; J A Shafer
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

5.  Cleavage of human cytomegalovirus protease pUL80a at internal and cryptic sites is not essential but enhances infectivity.

Authors:  Amy N Loveland; Chee-Kai Chan; Edward J Brignole; Wade Gibson
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

6.  Novel yeast cell-based assay to screen for inhibitors of human cytomegalovirus protease in a high-throughput format.

Authors:  Valérie Cottier; Alcide Barberis; Urs Lüthi
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

7.  Substrate modulation of enzyme activity in the herpesvirus protease family.

Authors:  Ana Lazic; David H Goetz; Anson M Nomura; Alan B Marnett; Charles S Craik
Journal:  J Mol Biol       Date:  2007-08-16       Impact factor: 5.469

8.  Enzymatic activities of human cytomegalovirus maturational protease assemblin and its precursor (pPR, pUL80a) are comparable: [corrected] maximal activity of pPR requires self-interaction through its scaffolding domain.

Authors:  Edward J Brignole; Wade Gibson
Journal:  J Virol       Date:  2007-02-07       Impact factor: 5.103

Review 9.  Unconventional serine proteases: variations on the catalytic Ser/His/Asp triad configuration.

Authors:  Ozlem Doğan Ekici; Mark Paetzel; Ross E Dalbey
Journal:  Protein Sci       Date:  2008-09-29       Impact factor: 6.725

10.  Cytomegalovirus assemblin (pUL80a): cleavage at internal site not essential for virus growth; proteinase absent from virions.

Authors:  Chee-Kai Chan; Edward J Brignole; Wade Gibson
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.